nach oben

Drug Safety

Erschienen in:

01.06.2003 | Review Article

Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma

verfasst von: Dr Luis García-Marcos, Antje Schuster, Eduardo G. Pérez-Yarza

Erschienen in: Drug Safety | Ausgabe 7/2003

Einloggen, um Zugang zu erhalten

Abstract

Antileukotrienes are a relatively new class of anti-asthma drugs that either block leukotriene synthesis (5-lipoxygenase inhibitors) like zileuton, or antagonise the most relevant of their receptors (the cysteinyl leukotriene 1 receptor [CysLT1]) like montelukast, zafirlukast or pranlukast. Hence, their major effect is an anti-inflammatory one. With the exception of pranlukast, the other antileukotrienes have been studied and marketed in the US and Europe for long enough to establish that they are useful drugs in the management of asthma. Their effects, significantly better than placebo, seem more pronounced in subjective measurements (i.e. symptoms scores or quality-of-life tests) than in objective parameters (i.e. forced expiratory volume in 1 second or peak expiratory flow rate). Also, there is some evidence that these drugs work better in some subsets of patients with certain genetic polymorphisms — probably related to their leukotriene metabolism — or patients with certain asthma characteristics. There are a small number of comparative studies only, and with regard to long-term asthma control differences between the agents have not been evaluated. Nevertheless, their overall effect appears comparable with sodium cromoglycate (cromolyn sodium) or theophylline, but significantly less than low-dose inhaled corticosteroids. Antileukotrienes have been shown to have a degree of corticosteroid-sparing effect, but salmeterol appears to perform better as an add-on drug. Montelukast is probably the most useful antileukotriene for continuous treatment of exercise-induced asthma, performing as well as salmeterol without inducing any tolerance. All antileukotrienes are taken orally; their frequency of administration is quite different ranging from four times daily (zileuton) to once daily (montelukast). Antileukotrienes are well tolerated drugs, even though zileuton intake has been related to transitional liver enzyme elevations in some cases. Also Churg-Strauss syndrome (a systemic vasculitis), has been described in small numbers of patients taking CysLTl antagonists. It is quite probable that this disease appears as a consequence of an ‘unmasking’ effect when corticosteroid dosages are reduced in patients with severe asthma once CysLT1 antagonists are introduced, but more data are needed to definitely establish the mechanism behind this effect. Overall, however, the benefits of antileukotrienes in the treatment of asthma greatly outweigh their risks.

Guidelines for the diagnosis and management of asthma. Update on selected topics: 2002. National Institutes of Health National Heart, Lung, and Blood Institute National asthma education and prevention program. Maryland, USA: Bethseda, 2002 Jun

Global Strategy for Asthma Management and Prevention. National Institutes of Health National Heart, Lung, and Blood Institute. Maryland, USA: Bethseda, 2002

Garcia-Marcos L, Schuster A. New perspectives for asthma treatment: anti-leukotriene drugs. Pediatr Allergy Immunol 1999 May; 10(2): 77–88PubMedCrossRef

Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987 Oct; 136(4): 985–98PubMedCrossRef

Leff AR. Discovery of leukotrienes and development of antileukotriene agents. Ann Allergy Asthma Immunol 2001 Jun; 86(6 Suppl. 1): 4–8PubMedCrossRef

Ravasi S, Capra V, Panigalli T, et al. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol 2002 Apr 15; 63(8): 1537–46PubMedCrossRef

Ravasi S, Capra V, Mezzetti M, et al. A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Mol Pharmacol 2000 Jun; 57(6): 1182–9PubMed

Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996 Aug; 26(8): 868–79PubMedCrossRef

Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001 May 1; 119(5): 1533–46PubMedCrossRef

10.

Merck Frost Canada & Co. Singulair product monograph. Kirkland (PQ), Canada, 2002 Apr

11.

Zeneca Pharmaceuticals. Zafirlukast product monograph. Cheshire, UK: 1997 Aug

12.

Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001; 61(2): 285–315PubMedCrossRef

13.

Abbot Laboratories. Zyflo Filmtab product monograph. North Chicago ( IL), 1998 Mar

14.

Brocks DR, Upward J, Davy M, et al. Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. Br J Clin Pharmacol 1997 Sep; 44(3): 289–91PubMedCrossRef

15.

Brocks DR, Upward J, Hust R, et al. The pharmacokinetics of pranlukast in healthy young and elderly subjects. Int J Clin Pharmacol Ther 1996 Sep; 34(9): 375–9PubMed

16.

Schoors DF, De Smet M, Reiss T, et al. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995 Sep; 40(3): 277–80PubMedCrossRef

17.

Zhao JJ, Rogers JD, Holland SD, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997 Dec; 18(9): 769–77PubMedCrossRef

18.

Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996 Mar; 13(3): 445–8PubMedCrossRef

19.

Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999 May; 39(5): 495–500PubMed

20.

Malmstrom K, Schwartz J, Reiss TF, et al. Effect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther 1998 May; 5(3): 189–95PubMedCrossRef

21.

Depre M, Van Hecken A, Verbesselt R, et al. Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999 Sep; 39(9): 941–4PubMedCrossRef

22.

Merck Sharp and Dohme. Montelukast product monograph. New Jersey, USA: 1998 Mar

23.

Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000 Apr; 59(4): 891–928PubMedCrossRef

24.

Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999 Jan 2; 353(9146): 57–62PubMedCrossRef

25.

Brocks DR, Upward JW, Georgiou P, et al. The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur J Clin Pharmacol 1996; 51(3-4): 303–8PubMedCrossRef

26.

Wong SL, Awni WM, Cavanaugh JH, et al. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet 1995; 29Suppl. 2: 9–21PubMedCrossRef

27.

Awni WM, Braeckman RA, Granneman GR, et al. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet 1995; 29Suppl. 2: 22–33PubMedCrossRef

28.

Awni WM, Cavanaugh JH, Tzeng TB, et al. Pharmacokinetic interactions between zileuton and prednisone. Clin Pharmacokinet 1995; 29Suppl. 2: 105–11PubMedCrossRef

29.

Awni WM, Cavanaugh JH, Leese P, et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997; 52(1): 49–54PubMedCrossRef

30.

Awni WM, Hussein Z, Cavanaugh JH, et al. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin Pharmacokinet 1995; 29Suppl. 2: 92–7PubMedCrossRef

31.

Awni WM, Braeckman RA, Locke CS, et al. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin Pharmacokinet 1995; 29Suppl. 2: 98–104PubMedCrossRef

32.

Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995; 29Suppl. 2: 77–83PubMedCrossRef

33.

Awni WM, Hussein Z, Granneman GR, et al. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 1995; 29Suppl. 2: 67–76PubMedCrossRef

34.

Braeckman RA, Granneman GR, Locke CS, et al. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet 1995; 29Suppl. 2: 42–8PubMedCrossRef

35.

Awni WM, Cavanaugh JH, Witt G, et al. The effect of food on the pharmacokinetics of zileuton. Clin Pharmacokinet 1995; 29Suppl. 2: 62–6PubMedCrossRef

36.

Awni WM, Locke C, Dube LM, et al. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. J Clin Pharmacol 1997 May; 37(5): 388–94PubMed

37.

Awni WM, Wong S, Chu SY, et al. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. J Clin Pharmacol 1997 May; 37(5): 395–404PubMed

38.

Awni WM, Cavanaugh JH, Braeckman RA, et al. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Clin Pharmacokinet 1995; 29Suppl. 2: 49–61PubMedCrossRef

39.

Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991 May 4; 337(8749): 1062–3PubMedCrossRef

40.

Dempsey OJ, Wilson AM, Sims EJ, et al. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000 Apr; 117(4): 950–3PubMedCrossRef

41.

Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476): a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997 Jan; 52(1): 45–8PubMedCrossRef

42.

Schwartz HJ, Petty T, Dube LM, et al. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. Arch Intern Med 1998 Jan 26; 158(2): 141–8PubMedCrossRef

43.

Kemp JP, Korenblat PE, Scherger JE, et al. Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. J Fam Pract 1999 Jun; 48(6): 425–32PubMed

44.

Dockhorn RJ, Baumgartner RA, Leff JA, et al. Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax 2000 Apr; 55(4): 260–5PubMedCrossRef

45.

Smith LJ, Geller S, Ebright L, et al. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990 Apr; 141(4 Pt 1): 988–92PubMed

46.

Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993 Oct; 54(4): 430–6PubMedCrossRef

47.

Smith LJ, Hanby LA, Lavins BJ, et al. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 1998 Jul; 81(1): 43–9PubMedCrossRef

48.

O’Shaughnessy TC, Georgiou P, Howland K, et al. Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax 1997 Jun; 52(6): 519–22PubMedCrossRef

49.

De Lepeleire I, Reiss TF, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997 Jan; 61(1): 83–92PubMedCrossRef

50.

Taylor IK, O’Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991 Mar 23; 337(8743): 690–4PubMedCrossRef

51.

Findlay SR, Barden JM, Easley CB, et al. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992 May; 89(5): 1040–5PubMedCrossRef

52.

Dahlen B, Zetterstrom O, Bjorck T, et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994 Feb; 7(2): 324–31PubMedCrossRef

53.

Phipatanakul W, Eggleston PA, Conover-Walker MK, et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol 2000 Apr; 105(4): 704–10PubMedCrossRef

54.

Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997 Jun; 155(6): 1856–63PubMed

55.

O’Shaughnessy KM, Taylor IK, O’Connor B, et al. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993 Jun; 147(6 Pt 1): 1431–5PubMed

56.

Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994 Feb; 105(2): 483–8PubMedCrossRef

57.

Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993 Oct; 92(4): 507–12PubMedCrossRef

58.

Okudaira H. Challenge studies of a leukotriene receptor antagonist. Chest 1997 Feb; 111(2 Suppl.): 46S–51SPubMedCrossRef

59.

Hamilton A, Faiferman I, Stober P, et al. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998 Aug; 102(2): 177–83PubMedCrossRef

60.

Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999 Jan; 29(1): 42–51PubMedCrossRef

61.

Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991 Mar; 46(3): 184–9PubMedCrossRef

62.

Dekhuijzen PN, Bootsma GP, Wielders PL, et al. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. Eur Respir J 1997 Dec; 10(12): 2749–53PubMedCrossRef

63.

Yoshida S, Ishizaki Y, Shoji T, et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000 Jul; 30(7): 1008–14PubMedCrossRef

64.

Yoshida S, Sakamoto H, Ishizaki Y, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000 Jan; 30(1): 64–70PubMedCrossRef

65.

Ishioka S, Hozawa S, Haruta Y, et al. Effects of pranlukast, a cysteinyl leukotriene antagonist, on bronchial responsiveness to methacholine in aspirin-intolerant asthmatics treated with corticosteroids. Hiroshima J Med Sci 2000 Jun; 49(2): 105–8PubMed

66.

Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002 Jan; 109(1): 68–74PubMedCrossRef

67.

Lipworth BJ, Dempsey OJ, Aziz I, et al. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. Am J Med 2000 Aug 1; 109(2): 114–21PubMedCrossRef

68.

Gomez FP, Iglesia R, Roca J, et al. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1): 1559–64PubMed

69.

Kidney JC, Ridge SM, Chung KF, et al. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993 Jan; 147(1): 215–7PubMedCrossRef

70.

Nagase T, Ishii S, Katayama H, et al. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor: roles of thromboxanes and leukotrienes. Am J Respir Crit Care Med 1997 Nov; 156(5): 1621–7PubMed

71.

Rorke S, Jennison S, Jeffs JA, et al. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax 2002 Apr; 57(4): 323–7PubMedCrossRef

72.

Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996 Sep; 98(3): 528–34PubMedCrossRef

73.

Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999 Mar 16; 130(6): 487–95PubMed

74.

Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002 Mar; 121(3): 732–8PubMedCrossRef

75.

Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999 Jul; 14(1): 12–8PubMedCrossRef

76.

Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001 Sep; 108(3): E48PubMedCrossRef

77.

Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998 Dec; 102(6 Pt 1): 935–42PubMedCrossRef

78.

Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1): 1381–9PubMed

79.

Kane GC, Tollino M, Pollice M, et al. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins 1995 Jul; 50(1): 1–18PubMedCrossRef

80.

Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996 Feb; 97(2): 646–54PubMedCrossRef

81.

Nakamura Y, Hoshino M, Sim JJ, et al. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998 Oct; 53(10): 835–41PubMedCrossRef

82.

Kodani M, Sakata N, Takano Y, et al. Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes. Immunopharmacology 2000 Sep; 49(3): 263–74PubMedCrossRef

83.

Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997 Apr; 155(4): 1235–40PubMed

84.

Horiguchi T, Tachikawa S, Kasahara J, et al. Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma. Arzneimittel Forschung 1999 Jan; 49(1): 35–7PubMed

85.

Kobayashi H, Takahashi Y, Mitsufuji H, et al. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast. Jpn J Physiol 1999 Dec; 49(6): 541–4PubMedCrossRef

86.

Yamauchi K, Tanifuji Y, Pan LH, et al. Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. J Asthma 2001 Feb; 38(1): 51–7PubMedCrossRef

87.

Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999 Oct; 160(4): 1227–31PubMed

88.

Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999 Dec; 28(6): 402–7PubMedCrossRef

89.

Henderson Jr WR, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002 Jan 1; 165(1): 108–16PubMed

90.

Dessanges JF, Prefaut C, Taytard A, et al. The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. J Allergy Clin Immunol 1999 Dec; 104(6): 1155–61PubMedCrossRef

91.

Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999 Mar; 134(3): 273–9PubMedCrossRef

92.

Coreno A, Skowronski M, Kotaru C, et al. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 2000 Sep; 106(3): 500–6PubMedCrossRef

93.

Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000 Jan 18; 132(2): 97–104PubMed

94.

Villaran C, O’Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999 Sep; 104(3 Pt 1): 547–53PubMedCrossRef

95.

Bronsky EA, Kemp JP, Zhang J, et al. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997 Nov; 62(5): 556–61PubMedCrossRef

96.

Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997 Dec; 52(12): 1030–5PubMedCrossRef

97.

Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998 Jul 16; 339(3): 147–52PubMedCrossRef

98.

Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998 Jul 16; 339(3): 141–6PubMedCrossRef

99.

Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997 May; 99(5): 655–9PubMedCrossRef

100.

Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000 Jul; 162(1): 187–90PubMed

101.

Suguro H, Majima T, Ichimura K, et al. Effect of a leukotriene antagonist, pranlukast hydrate, on exercise-induced bronchoconstriction [abstract]. Am J Respir Crit Care Med 1997; 155: A662

102.

Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996 Mar; 153(3): 931–5PubMed

103.

Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994 Sep; 150(3): 618–23PubMed

104.

Pearlman DS, Lampl KL, Dowling Jr PJ, et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000 Jun; 22(6): 732–47PubMedCrossRef

105.

Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000 Jun; 55(6): 478–83PubMedCrossRef

106.

Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997 Jul; 19(4): 675–90PubMedCrossRef

107.

Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997 Feb 1; 126(3): 177–83PubMed

108.

Tashkin DP, Nathan RA, Howland WC, et al. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. J Allergy Clin Immunol 1999 Feb; 103(2 Pt 1): 246–54PubMedCrossRef

109.

Kemp JP, Minkwitz MC, Bonuccelli CM, et al. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999 Feb; 115(2): 336–42PubMedCrossRef

110.

Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998 Jul; 102(1): 50–6PubMedCrossRef

111.

Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998 Jun; 11(6): 1232–9PubMedCrossRef

112.

Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998 Jun 8; 158(11): 1213–20PubMedCrossRef

113.

Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998 Apr 15; 279(15): 1181–6PubMedCrossRef

114.

Grossman J, Faiferman I, Dubb JW, et al. Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34(4): 321–8PubMedCrossRef

115.

Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997 Jun; 52(6): 523–7PubMedCrossRef

116.

Yoo SH, Park SH, Song JS, et al. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology 2001 Mar; 6(1): 15–21PubMedCrossRef

117.

Obase Y, Shimoda T, Tomari S, et al. Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study. Ann Allergy Asthma Immunol 2001 Jul; 87(1): 43–7PubMedCrossRef

118.

Tomari S, Shimoda T, Kawano T, et al. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 2001 Aug; 87(2): 156–61PubMedCrossRef

119.

Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993 Dec 1; 119(11): 1059–66PubMed

120.

Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 1996 Nov; 98(5 Pt 1): 859–71PubMedCrossRef

121.

Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996 Mar 27; 275(12): 931–6PubMedCrossRef

122.

Lazarus SC, Lee T, Kemp JP, et al. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am J Manag Care 1998 Jun; 4(6): 841–8PubMed

123.

Holgate ST, Anderson KR, Rodgers EM. Comparison of Accolate™ (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients [abstract]. Allergy 1995; 50Suppl. 26: 319–20

124.

Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000 Jun; 105(6 Pt 1): 1123–9PubMedCrossRef

125.

Nathan RA, Bleecker ER, Kalberg C. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 2001 Aug 15; 111(3): 195–202PubMedCrossRef

126.

Busse W, Wolfe J, Storms W, et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract 2001 Jul; 50(7): 595–602PubMed

127.

Kim KT, Ginchansky EJ, Friedman BF, et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 2000 Nov; 85(5): 398–406PubMedCrossRef

128.

Westbroek J, Pasma HR. Effects of 2 weeks of treatment with fluticasone propionate 100μg b.d. by comparison with zafirlukast 20mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma. Respir Med 2000 Feb; 94(2): 112–8PubMedCrossRef

129.

Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001 Mar; 107(3): 461–8PubMedCrossRef

130.

Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002 Feb; 88(2): 227–35PubMedCrossRef

131.

Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001; 17(2): 96–104PubMed

132.

Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001 Jun; 31(6): 845–54PubMedCrossRef

133.

Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001 Mar; 95(3): 227–34PubMedCrossRef

134.

Wenzel S, Chervinsky P, Kerwin E. Oral pranlukast (Ultair) vs inhaled beclomethasone: results of a 12-week trial in patients with asthma [abstract]. Am J Respir Crit Care Med 1997; 155: A203

135.

Shan S, Galant S, Murray G. Pranlukast (Ultair) improves FEV1 in patients with asthma: results of of a 12-week multicenter study vs nedocromil [abstract]. Am J Respir Crit Care Med 1997; 155: A665

136.

Christian VJ, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000 Aug; 162(2 Pt 1): 578–85

137.

Ducharme F. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2001: CD003133

138.

Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999 Jun; 103(6): 1075–80PubMedCrossRef

139.

Nelson HS, Nathan RA, Kalberg C, et al. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. MedGenMed 2001 Jul 5; 3(4): 3PubMed

140.

Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999 Dec; 160(6): 1862–8PubMed

141.

Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999 Jul 10; 319(7202): 87–90PubMedCrossRef

142.

Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001 Jun 23; 357(9273): 2007–11PubMedCrossRef

143.

Mathison DA, Koziol JA. Marginal utility of montelukast for persistent asthma. Chest 2002 Feb; 121(2): 334–7PubMedCrossRef

144.

Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001 May; 138(5): 694–8PubMedCrossRef

145.

Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Respir Med 2000 Jun; 94(6): 612–21PubMedCrossRef

146.

Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001 Apr; 119(4): 1021–6PubMedCrossRef

147.

Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000 Dec; 106(6): 1088–95PubMedCrossRef

148.

Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001 Aug; 120(2): 423–30PubMedCrossRef

149.

Stempel DA, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002 Mar; 109(3): 433–9PubMedCrossRef

150.

Oosaki R, Mizushima Y, Kashii T, et al. Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Immunol 1997 Sep; 114(1): 97–100PubMedCrossRef

151.

Yokoyama A, Kohno N, Sakai K, et al. Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids. J Asthma 1998; 35(1): 57–62PubMedCrossRef

152.

Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000 Oct; 55Suppl. 2: S28–31PubMedCrossRef

153.

Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002 Jun; 109(6): 936–42PubMedCrossRef

154.

Fowler SJ, Hall IP, Wilson AM, et al. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002 Jun; 58(3): 187–90PubMedCrossRef

155.

Tanaka H, Saito T, Kurokawa K, et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-ketoprostaglandin (PG)F1alpha. Allergy 1999 May; 54(5): 489–94PubMedCrossRef

156.

Hasday JD, Meltzer SS, Moore WC, et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med 2000 Apr; 161(4 Pt 1): 1229–36PubMed

157.

Barnes NC. Clinical torelability of zafirlukast, a new oral antileukotriene drug. Eur Respir Rev 1998; 8(54): 194–8

158.

Knorr B, Larson P, Nguyen HH, et al. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999 Aug; 39(8): 786–93PubMedCrossRef

159.

Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001 Jan; 31(1): 77–87PubMedCrossRef

160.

Barnes NC, de Jong B, Miyamoto T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997 Feb; 111(2 Suppl.): 52S–60SPubMedCrossRef

161.

Churg J, Strauss L. Allergy granulomatosis, allergic angiitis and polyarteritis nodosa. Am J Pathol 1951; 27: 277–301PubMed

162.

Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984 Mar; 63(2): 65–81

163.

Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990 Aug; 33(8): 1094–100PubMedCrossRef

164.

Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994 Feb; 37(2): 187–92PubMedCrossRef

165.

Josefson D. Asthma drug linked with Churg-Strauss syndrome [news]. BMJ 1997 Aug 9; 315(7104): 330PubMed

166.

Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998 Feb 11; 279(6): 455–7PubMedCrossRef

167.

Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999 Mar; 103(3 Pt 1): 534–5PubMedCrossRef

168.

Hayashi S, Furuya S, Imamura H. Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal. Heart 2001 Sep; 86(3): E7PubMedCrossRef

169.

Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax 1999 Jun; 54(6): 558–60PubMedCrossRef

170.

Gruer P, Bold T, Vilardo L. Case 30-2000: Churg-Strauss syndrome. N Engl J Med 2001 Mar 15; 344(11): 858–9PubMedCrossRef

171.

Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995 Aug; 25(1): 28–34PubMedCrossRef

172.

Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000 Feb; 43(2): 414–9PubMedCrossRef

173.

Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998 Mar; 91(3): 219–29PubMedCrossRef

174.

Martin R, Wilton L, Mann R. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 nprecription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999 May 1; 8(3): 179–89PubMedCrossRef

175.

Lilly CM, Churg A, Lazarovich M, et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol 2002 Jan; 109(1): S1–19PubMedCrossRef

176.

Loughlin JE, Cole JA, Rothman KJ, et al. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002 Mar; 88(3): 319–25PubMedCrossRef

177.

Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000 Mar; 117(3): 708–13PubMedCrossRef

178.

Wechsler ME, Drazen JM. Leukotriene modifiers adn Churg-Strauss syndrome: an update [abstract]. Am J Respir Crit Care Med 2000; 161: A195

179.

Churg A, Churg J. Steroids and Churg-Strauss syndrome. Lancet 1998 Jul 4; 352(9121): 32–3PubMedCrossRef

180.

Donohue JF. Montelukast and Churg-Strauss syndrome [letter]. Chest 2001 Feb; 119(2): 668PubMedCrossRef

181.

Stoloff S, Stempel DA. Churg-Strauss syndrome: is there an association with leukotriene modifiers? Chest 2000 Nov; 118(5): 1515–6PubMedCrossRef

182.

Lipworth BJ, Wilson AM. Montelukast and Churg-Strauss syndrome [letter]. Thorax 2001 Mar; 56(3): 244PubMedCrossRef

183.

Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000 Sep; 55(9): 805–6PubMedCrossRef

184.

Villena V, Hidalgo R, Sotelo MT, et al. Montelukast and Churg-Strauss syndrome [letter]. Eur Respir J 2000 Mar; 15(3): 626PubMedCrossRef

185.

Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999 Feb 27; 353(9154): 725–6PubMedCrossRef

186.

Katz RS, Papernik M. Zafirlukast and Churg-Strauss syndrome [letter]. JAMA 1998 Jun 24; 279(24): 1949PubMedCrossRef

187.

Sabio JM, Jimenez-Alonso J, Gonzalez-Crespo F. More about Churg-Strauss syndrome and montelukast treatment [letter]. Chest 2001 Dec; 120(6): 2116PubMedCrossRef

188.

Solans R, Bosch JA, Selva A, et al. Montelukast and Churg-Strauss syndrome. Thorax 2002 Feb; 57(2): 183–5PubMedCrossRef

189.

Finkel TH, Hunter DJ, Paisley JE, et al. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol 1999 Mar; 103(3 Pt 1): 533–4PubMedCrossRef

190.

Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002 Feb; 31(4): 218–27PubMedCrossRef

191.

Termeer C, Simon JC, Schopf E. Churg-Strauss syndrome associated with fluticasone therapy. Arch Dermatol 2001 Nov; 137(11): 1527–8PubMedCrossRef

192.

Hubner C, Dietz A, Stremmel W, et al. Macrolide induced Churg-Strauss syndrome in a patient with atopy [abstract]. Lancet 1997; 350: 563PubMedCrossRef

193.

Imai H, Nakamoto Y, Hirokawa M, et al. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron 1989; 51(3): 405–8PubMedCrossRef

194.

Orriols R, Munoz X, Ferrer J, et al. Cocaine-induced Churg-Strauss vasculitis. Eur Respir J 1996 Jan; 9(1): 175–7PubMedCrossRef

195.

Hashimoto M, Fujishima T, Tanaka H, et al. Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma. Intern Med 2001 May; 40(5): 432–4PubMedCrossRef

196.

Baba K, Niwa S, Yagi T, et al. [Churg-Strauss syndrome during corticosteroid tapering in a patient with bronchial asthma receiving pranlukast]. Arerugi 2000 Jun; 49(6): 512–5PubMed

197.

Honsinger RW. Zafirlukast and Churg-Strauss syndrome. JAMA 1998 Jun 24; 279(24): 1949PubMedCrossRef

198.

Spada CS, Krauss AH, Nieves AL, et al. Effects of leukotrienes B4 (LTB4) and D4 (LTD4) on motility of isolated normodense human eosinophils and neutrophils. Adv Exp Med Biol 1997; 400B: 699–706PubMed

Titel: Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma
verfasst von: Dr Luis García-Marcos
Antje Schuster
Eduardo G. Pérez-Yarza
Publikationsdatum: 01.06.2003
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 7/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200326070-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2003

Important Drug Safety Information on the Internet

Cardiovascular Safety of Sildenafil

Benefits and Risks of Pharmacological Treatments for Essential Tremor

Medication Errors Caused by Confusion of Drug Names